Brendan M. O’Leary, PhD, is the Executive Vice Chancellor for Innovation and Business Development at the University of Massachusetts Medical School (UMMS).
This newly-created position reflects the medical school’s institutional emphasis on developing a comprehensive and multi-faceted business strategy that promotes innovation, supports entrepreneurship, optimizes the institution’s research portfolio, and leverages the wide array of expertise and capabilities that exist throughout our academic community. O’Leary engages with all key campus stakeholders, internally and externally, to diversify and expand business ventures, enlarge commercialization efforts, enhance entrepreneurial activities, and drive new strategic partnerships. He also oversees the Office of Technology Management, where he is responsible for structuring, negotiating and implementing business transactions, as well as for protecting and fully leveraging the institution’s intellectual property portfolio.
O’Leary joined UMMS in December 2014 from Prism Venture Management, a Boston-area venture capital firm with over $1.25B under management, where he led the firm’s life sciences practice. During an almost 12 year tenure there, he actively evaluated and mentored hundreds of life science companies, taking investment positions and board seats at many of those companies. A sample of his Prism investments includes: Alacer Biomedical Inc. (acquired by Allergan), Atritech (acquired by Boston Scientific), BioRexis Pharmaceutical Corp. (acquired by Pfizer), Proteon Therapeutics (NASDAQ: PRTO), Serica Technologies (acquired by Allergan), and Trius Therapeutics (NASDAQ: TSRX; acquired by Cubist).
O’Leary began his professional career with numerous roles at IGEN International, a medical diagnostics company (acquired by Roche) and Meso Scale Discovery, a high-throughput drug discovery start-up. He is an accomplished scientist with numerous publications, inventions, and commercialized products to his credit.
O’Leary holds a PhD in organic chemistry from the Massachusetts Institute of Technology and a BA in chemistry and economics from Middlebury College and he was a Kauffman Fellow.